

Antimicrobial Susceptibility Testing Market worth \$5.67 billion by 2030 - Exclusive Report by 360iResearch

The Global Antimicrobial Susceptibility Testing Market to grow from USD 3.61 billion in 2022 to USD 5.67 billion by 2030, at a CAGR of 5.80%.


PUNE, MAHARASHTRA, INDIA ,
November 8, 2023 /EINPresswire.com/
-- The "[Antimicrobial Susceptibility Testing Market](#) by Product Type (Automated Products, Consumables, Manual Products), Method (Agar Dilution, Disks Diffusion, ETEST), Type, Application, End-User - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Antimicrobial Susceptibility Testing Market to grow from USD 3.61 billion in 2022 to USD 5.67 billion by 2030, at a CAGR of 5.80%.

Request a Free Sample Report @

https://www.360iresearch.com/library/intelligence/antimicrobial-susceptibility-testing?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Antimicrobial susceptibility testing (AST) determines the effectiveness of antibiotics or other antimicrobial drugs against microorganisms such as bacteria, fungi, and viruses. This testing method is an essential tool for guiding the selection of appropriate antibiotics used in treating infectious diseases and monitoring the emergence of drug-resistant strains of microorganisms. The market is experiencing growth due to various factors, including the rising incidence of infectious disorders, the growing adoption of point-of-care testing facilities, and the surging demand for prompt and precise detection of antibiotic resistance. However, challenges affecting the expansion of the AST market comprise high costs associated with advanced technologies such as molecular diagnostics instruments or automated systems, limiting their adoption by



small-scale laboratories. In addition, limited access to robust healthcare infrastructure in developing countries, insufficient funding for research and development (R&D), lack of skilled professionals in the field, and variation in regulatory policies among different regions affecting market entry or expansion efforts are the additional obstacles affecting the expansion of the market. Additionally building partnerships between industry stakeholders such as diagnostic manufacturers, healthcare providers researchers and pharmaceutical companies can streamline processes while driving advancements in AST technologies. Moreover, the increasing demand for accurate and timely diagnosis of infectious diseases is expected to create lucrative opportunities for the market, particularly with the technological advancement in disease diagnosis testing techniques and the introduction of new genomic identification methods.

Application: Rapid and extreme utilization of the AST in clinical diagnostics and drug discovery and development

AST is widely used in clinical diagnostics to determine the appropriate antibiotic treatment for patients and to identify the effectiveness of antibiotics against a specific microorganism. These diagnostics decrease the risk of treatment failure, reduce the duration of hospitalization, and minimize the development of antibiotic resistance. Moreover, AST is used to evaluate the efficacy of new antibiotics and determine the minimum inhibitory concentration (MIC) of new drugs. In context, this information is valuable in determining the appropriate dosage of the drug and the potential for developing antibiotic resistance.

Method: Development of qualitative AST techniques with increased accuracy of the tests
The disk diffusion method involves placing antibiotic disks onto agar plates inoculated with microorganism testing. The plates are incubated, and the absence or presence of an inhibition zone around the disk is utilized to define the susceptibility or resistance of the microorganism to the antibiotic. The Epsilometer test (E-test) method involves using a plastic strip containing a gradient of antibiotic concentrations. The minimum inhibitory concentration (MIC) after incubation of the antibiotic is determined by locating the point where the ellipse intersects the strip. Rapid automation method systems use various techniques, including optical detection and impedance measurement, to provide accurate and timely results.

Type: Significant advancements in antifungal susceptibility testing due to heightened awareness of invasive fungal infections

Antimicrobial susceptibility testing is vital in determining effective treatments for microbial infections that focus on antibacterial, antifungal, and antiparasitic susceptibility testing. Antibacterial susceptibility testing is crucial in managing bacterial infections by identifying suitable antibiotics against specific bacterial strains. Additionally, antifungal susceptibility testing guides treatment for fungal infections caused by *Candida*, *Aspergillus*, and other pathogenic fungi. Moreover, antiparasitic susceptibility testing determines the effectiveness of antiparasitic drugs against infections caused by parasites such as *Plasmodium* (malaria), *Leishmania*, and *Trypanosoma* species.

Product Type: Advancement in the automated tools and consumables for early diagnosing and

treatment of the infectious diseases

Automated products use various methods such as fluorescence, spectrophotometry, and automated imaging to detect microbial growth and identify the susceptibility of microorganisms to different antibiotics. Manual products include various consumables, such as minimum inhibitory concentration (MIC) strips, susceptibility discs, and susceptibility plates. Manual products are widely used in healthcare facilities, particularly in resource-limited settings where automated systems are not available or cost-effective. Manual testing methods produce accurate results and are an important tool in diagnosing and treating infectious diseases. However, these testing methods are more time-consuming and subjective compared to automated systems.

End-User: Extensive use of AST in hospitals and diagnostic laboratories

Hospitals and diagnostic laboratories use antimicrobial susceptibility testing to diagnose and select treatments accurately. Hospitals and diagnostic laboratories perform antimicrobial testing on various sample types, including blood, urine, and sputum. Pharmaceutical and biotechnology companies use antimicrobial susceptibility testing for drug development processes, as it helps to identify promising candidates for further study.

Regional Insights:

The Americas and Europe are significant regions in the global antimicrobial susceptibility testing market due to the rise in infectious diseases and advanced healthcare infrastructure. The Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN), which tracks antimicrobial resistance patterns in nationwide healthcare facilities, promotes AST adoption while ensuring high-quality data collection. In Latin America, significant progress is observed in the field of antimicrobial susceptibility testing (AST), with countries such as Brazil adopting and executing guidelines established by the Clinical & Laboratory Standards Institute (CLSI). This crucial development contributes to the global efforts in combating antimicrobial resistance, thereby ensuring effective treatment options for bacterial infections. Furthermore, the European Centre for Disease Prevention and Control (ECDC) plays a pivotal role in tracking resistance patterns across Europe through its European Antimicrobial Resistance Surveillance Network (EARS-Net). The Asia-Pacific (APAC) is expected to experience substantial growth in the market due to rising awareness about infectious diseases, increasing healthcare expenditure, and emerging drug-resistant microorganisms. China, Japan, and India are the major markets for antimicrobial susceptibility testing within the Asia-Pacific. These nations have a high burden of infectious diseases and a large population, which is expected to drive the demand for AST products and services. Moreover, government initiatives worldwide to control infectious diseases and rising investments & funding in healthcare infrastructure are expected to bolster the market growth in the APAC.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Antimicrobial Susceptibility Testing Market. It provides a comprehensive evaluation of vendors by examining key metrics within

Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Antimicrobial Susceptibility Testing Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Accelerate Diagnostics, Inc., Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE Tibbi Malz. San. ve Tic. Ltd. Sti., BioMérieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, Danaher Corporation, ELITech Group SAS, Erba Lachema s.r.o., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Leading Biology, Inc., Liofilchem S.r.l., Mast Group Ltd., MP Biomedicals, LLC, Pfizer Inc., Qiagen N.V., QuantaMatrix Inc., Rapid Test Methods Ltd., Resistell AG, Synoptics Group, Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/antimicrobial-susceptibility-testing?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Antimicrobial Susceptibility Testing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product Type, market is studied across Automated Products, Consumables, and Manual Products. The Manual Products is further studied across Minimum Inhibitory Concentration (MIC) Strips, Susceptibility Discs, and Susceptibility Plates. The Automated Products commanded largest market share of 39.83% in 2022, followed by Consumables.

Based on Method, market is studied across Agar Dilution, Disks Diffusion, ETEST, Genotyping Methods, and Rapid Automation Method. The ETEST commanded largest market share of 29.60% in 2022, followed by Disks Diffusion.

Based on Type, market is studied across Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, and Antiparasitic Susceptibility Testing. The Antibacterial Susceptibility Testing commanded largest market share of 57.92% in 2022, followed by Antifungal Susceptibility Testing.

Based on Application, market is studied across Clinical Diagnostics, Drug Discovery & Development, and Epidemiology. The Clinical Diagnostics commanded largest market share of 48.92% in 2022, followed by Drug Discovery & Development.

Based on End-User, market is studied across Contract Research Organizations, Hospital & Diagnostic Centers, Pharmaceutical & Biotechnology, and Research & Academic Institutes. The Pharmaceutical & Biotechnology commanded largest market share of 36.54% in 2022, followed by Contract Research Organizations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.52% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Antimicrobial Susceptibility Testing Market, by Product Type
7. Antimicrobial Susceptibility Testing Market, by Method
8. Antimicrobial Susceptibility Testing Market, by Type
9. Antimicrobial Susceptibility Testing Market, by Application
10. Antimicrobial Susceptibility Testing Market, by End-User
11. Americas Antimicrobial Susceptibility Testing Market
12. Asia-Pacific Antimicrobial Susceptibility Testing Market
13. Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market
14. Competitive Landscape
15. Competitive Portfolio

16. Appendix

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Antimicrobial Susceptibility Testing Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Antimicrobial Susceptibility Testing Market?
3. What is the competitive strategic window for opportunities in the Antimicrobial Susceptibility Testing Market?
4. What are the technology trends and regulatory frameworks in the Antimicrobial Susceptibility Testing Market?
5. What is the market share of the leading vendors in the Antimicrobial Susceptibility Testing Market?
6. What modes and strategic moves are considered suitable for entering the Antimicrobial Susceptibility Testing Market?

Read More @ https://www.360iresearch.com/library/intelligence/antimicrobial-susceptibility-testing?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch.com

This press release can be viewed online at: <https://www.einpresswire.com/article/667109541>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.